Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 8/20 | 0.45 |
| ▸ | CLK2 | P49760 | 10/20 | 0.44 |
| ▸ | CLK3 | P49761 | 9/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370182 | 0.91 | WNT1 (0.45) | WNT1CLK2CLK3DYRK1ATGFBR1 | |
| SCHEMBL12370049 | 0.90 | CLK2 (0.45) | WNT1CLK2CLK3DYRK1APIK3CB | |
| SCHEMBL12370094 | 0.89 | CLK2 (0.46) | WNT1CLK2CLK3DYRK1APIK3CB | |
| SCHEMBL12370161 | 0.89 | CLK2 (0.48) | WNT1CLK2CLK3DYRK1ATGFBR1 | |
| SCHEMBL12370337 | 0.88 | CLK2 (0.47) | WNT1CLK2CLK3DYRK1ATGFBR1 | |
| SCHEMBL12369945 | 0.87 | CLK2 (0.48) | WNT1CLK2CLK3DYRK1APIK3CB | |
| SCHEMBL12370142 | 0.86 | CLK2 (0.55) | WNT1CLK2CLK3DYRK1ATGFBR1 | |
| SCHEMBL12370134 | 0.86 | CLK2 (0.52) | WNT1CLK2CLK3DYRK1ATGFBR1 | |
| SCHEMBL12370070 | 0.86 | CLK2 (0.42) | WNT1CLK2CLK3DYRK1ATGFBR1 | |
| SCHEMBL12370003 | 0.86 | WNT1 (0.51) | WNT1CLK2CLK3DYRK1ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855272-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3001903-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170202846-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-07-20 | — | — | US | disclosed |
| US-20170202846-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-07-20 | — | — | US | disclosed |
| US-9446035-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446035-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160101092-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-04-14 | — | — | US | disclosed |
| US-20160101092-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-04-14 | — | — | US | disclosed |
| US-9067939-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067939-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-8815897-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815897-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2013-11-07 | — | — | US | disclosed |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2013-11-07 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20160101092-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20170202846-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885CLK2 2380/4885CLK3 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.